PCA
CORT icon

Pallas Capital Advisors’s Corcept Therapeutics CORT Stock Holding History

Pallas Capital Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$515K Buy
+5,918
New +$357K 0.02% 558
2025
Q4 		– Sell
-4,556
Closed -$379K – 897
2025
Q3 		$379K Buy
4,556
+458
+11% +$33.1K 0.01% 604
2025
Q2 		$301K Buy
4,098
+84
+2% +$6.09K 0.01% 655
2025
Q1 		$458K Buy
+4,014
New +$244K 0.02% 491

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pallas Capital Advisors's CORT Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 5,918 shares worth $515K. The stake represents 0.02% of the portfolio and ranks #558 among its holdings. This is a return to the name: Pallas Capital Advisors previously reported a position in CORT as recently as Q3 2025.

Pallas Capital Advisors first reported a position in CORT in Q1 2025 and has held it in 4 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Pallas Capital Advisors held 5,918 shares of Corcept Therapeutics worth $515K as of Q2 2026.
  • Corcept Therapeutics was a new Pallas Capital Advisors position in Q2 2026.
  • Corcept Therapeutics made up 0.02% of Pallas Capital Advisors's portfolio in Q2 2026, its #558 holding.
  • Pallas Capital Advisors first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 4 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.